IHC also showed that CD3+ tumor‐infiltrating T cell percentages were higher in responding patients than nonresponding patients at day 39 posttreatment and a similar trend was found in CD3+CD8+ tumor‐infiltrating T cells, but this was not statistically significant. This evidence concerns the gene CD8A and neoplasm.